Literature DB >> 7057554

Placental theophylline transfer in pregnant asthmatics.

E Labovitz, S Spector.   

Abstract

The newborn's potential for xanthine toxic reactions from placental transfer of theophylline or caffeine conversion from theophylline was studied in 12 newborns of asthmatic mothers. Our results showed that maternal and cord theophylline levels were not notably different, yet heelstick levels tended to be higher than maternal levels. Newborn heelstick theophylline levels ranged from 2.3 to 19.6 microgram/mL with a mean of 10.5 microgram/mL. No caffeine conversion from theophylline was seen. Heart rate, Apgar scoring, and other parameters were not statistically different in babies whose mothers received theophylline compared with mildly asthmatic mothers not receiving theophylline and nonasthmatic mothers. Side effects in three babies with levels of theophylline greater than 10 microgram/mL were tachycardia and transient jitteriness. Newborns seem to tolerate theophylline levels corresponding to maternal levels without serious adversity; however, transient toxicity might occur with levels in the so-called therapeutic range.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7057554

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  11 in total

1.  Theophylline Pharmacokinetics in Foetal Sheep: Maternal Metabolic Capacity is the Principal Driver.

Authors:  Barent DuBois; Samantha Louey; George D Giraud; Ganesh Cherala; Sonnet S Jonker
Journal:  Basic Clin Pharmacol Toxicol       Date:  2015-03-19       Impact factor: 4.080

2.  Optimum management of asthma in pregnancy.

Authors:  H Mawhinney; S L Spector
Journal:  Drugs       Date:  1986-08       Impact factor: 9.546

3.  Placental transfer of theophylline in an in vitro closed perfusion system of human placenta isolated lobule.

Authors:  D Omarini; M M Barzago; A Bortolotti; G Lucchini; F Stellari; S Efrati; M Bonati
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1993 Oct-Dec       Impact factor: 2.441

4.  Longitudinal effects of pregnancy on the pharmacokinetics of theophylline.

Authors:  M J Gardner; M Schatz; L Cousins; R Zeiger; E Middleton; W J Jusko
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

Review 5.  Theophylline. Current thoughts on the risks and benefits of its use in asthma.

Authors:  S S Nasser; P J Rees
Journal:  Drug Saf       Date:  1993-01       Impact factor: 5.606

6.  A Possible Association between Oral Aminophylline Treatment during Pregnancy and Skeletal Congenital Abnormalities.

Authors:  Andrew E Czeizel; Erzsébet Puhó; Zoltán Bártfai; Akos Somoskövi
Journal:  Clin Drug Investig       Date:  2003       Impact factor: 2.859

7.  A physiologically based pharmacokinetic model for theophylline disposition in the pregnant and nonpregnant rat.

Authors:  J L Gabrielsson; L K Paalzow; L Nordström
Journal:  J Pharmacokinet Biopharm       Date:  1984-04

Review 8.  Clinical pharmacokinetics of vasodilators. Part II.

Authors:  R Kirsten; K Nelson; D Kirsten; B Heintz
Journal:  Clin Pharmacokinet       Date:  1998-07       Impact factor: 6.447

9.  Quercetin preventive effects on theophylline-induced anomalies in rat embryo.

Authors:  Neda Sistani Karampour; Ardeshir Arzi; Hossein Najafzadeh Varzi; Babak Mohammadian; Mohsen Rezaei
Journal:  Jundishapur J Nat Pharm Prod       Date:  2014-08-01

Review 10.  Asthma in Pregnancy: Pathophysiology, Diagnosis, Whole-Course Management, and Medication Safety.

Authors:  Huijie Wang; Na Li; Huaqiong Huang
Journal:  Can Respir J       Date:  2020-02-22       Impact factor: 2.409

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.